Basilea Pharmaceutica AG
SIX:BSLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Basilea Pharmaceutica AG
Net Issuance of Common Stock
Basilea Pharmaceutica AG
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Issuance of Common Stock
CHf617k
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-26%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Net Issuance of Common Stock
$152.5m
|
CAGR 3-Years
195%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Issuance of Common Stock
$426m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
22%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Net Issuance of Common Stock
CHf84.4m
|
CAGR 3-Years
517%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Issuance of Common Stock
CHf2.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Net Issuance of Common Stock
CHf187k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Net Issuance of Common Stock?
Net Issuance of Common Stock
617k
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Net Issuance of Common Stock amounts to 617k CHF.
What is Basilea Pharmaceutica AG's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-26%
Over the last year, the Net Issuance of Common Stock growth was -75%. The average annual Net Issuance of Common Stock growth rates for Basilea Pharmaceutica AG have been -48% over the past three years , -34% over the past five years , and -26% over the past ten years .
